Bio-Techne Corporation (TECH)

Market Cap	9.93B -18.3%
Revenue (ttm)	1.22B +1.6%
Net Income	81.06M -48.7%
EPS	0.52 -47.0%
Shares Out	156.45M
PE Ratio	122.22
Forward PE	30.69
Dividend	$0.32 (0.50%)
Ex-Dividend Date	Feb 13, 2026

Volume	2,467,686
Open	64.33
Previous Close	64.80
Day's Range	62.79 - 64.78
52-Week Range	46.01 - 72.16
Beta	1.47
Analysts	Buy
Price Target	72.67 (+14.5%)
Earnings Date	Feb 4, 2026

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,100
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Analyst Summary

According to 13 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $72.67, which is an increase of 14.50% from the latest price.

Price Target

$72.67

(14.50% upside)

Analyst Consensus: Buy